Critical Appraisal of International Guidelines for the Management of Diabetic Neuropathy: Is There Global Agreement in the Internet Era?

Table 6

Results of the assessment of the recommendations regarding treatment based on pathogenetic mechanisms using the AGREE II instrument (domain scores in %).

	D1	D2	D3	D4	D5	D6	Ave	Overall assessment
ADA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	N
UMHS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	N
AACE	50.0	33.3	0.0	0.0	0.0	16.7	16.7	N
PNICE	0.0	0.0	0.0	0.0	0.0	0.0	0.0	N
IDF	0.0	0.0	0.0	0.0	0.0	0.0	0.0	N
NZGG	0.0	0.0	0.0	0.0	0.0	0.0	0.0	N
AAN	55.6	22.2	0.0	21.0	8.8	4.2	18.6	N
TEPDN	33.3	27.8	0.0	33.3	0.0	25.0	19.9	N
SFD	0.0	27.8	14.6	38.9	25.0	25.0	21.9	N
SIGN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	N
EFNS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	N
NICE	0.0	0.0	0.0	0.0	0.0	0.0	0.0	N
SADA	55.6	0.0	4.2	51.4	4.2	0.0	19.2	N
Ave	15.0	8.5	1.4	11.1	2.9	5.5

Ave indicates average. SR indicates being strongly recommended for use in clinical practice. M indicates being recommended for use in clinical practice with some modifications. N indicates being not recommended for use in clinical practice.
D1 (domain 1) indicates scope and purpose; D2 (domain 2) indicates stakeholder involvement; D3 (domain 3) indicates rigor of development; D4 (domain 4) indicates clarity of presentation; D5 (domain 5) indicates applicability; D6 (domain 6) indicates editorial independence.